

e project provided:

B.4 What opportunities for training and professional development are

with his/her job or related to it?

Under the guidance of a supervisor and in accordance with


the organization's policies, procedures, and standards of practice, the


PRODUCTS

SPRINGS


PUBLICATIONS

INVESTMENT MANAGEMENT SERVICES AND FINANCIAL PRODUCTS PROVIDED BY PRUDENTIAL FINANCIAL SERVICES, INC. AND ITS AFFILIATES





D.2 PERSONNEL UPDATES
D.2.a Level of Effort



BIODIVERSITY CONSERVATION

Department of Biology, University of Toronto, 127 St. George Street, Toronto, Ontario M5S 1A5, Canada

25-2015/07/31

2009/08/7

New York Blood Center); Sara Lustigman (PI)

1 R01A1078314 03, NIH/NIAID (Sub-award from: Ne

uman onchocerciasis

The development of a recombinant vaccine against h

OTHER SUPPORT

ER J.

HOTEZ, PET

awarded:

New grants

Instituto Carlos III de la Salud - 10/21/17

Private Source 1/1/15 - 10/21/17

Grant ended:

Jan Government of Cuba - 10/21/17

CURRENT

EFFORT

10/21/17 - 10/21/17

The major goal of this project is to determine the genetic diversity of the virus in Latin America. The project will focus on the genetic diversity of the virus in Latin America. The project will focus on the genetic diversity of the virus in Latin America.

Sponsor: National Institutes of Health

Title: RBD Recombinant D

The transmission of hookworms is a major public health problem in developing countries. The development of a vaccine to complement the Human Hookworm Vaccine now under development by the Sabin PDP.

2012-10-15 12:16:16
Instituto Carlos Slim de la Salud 58873944
Initiative for Anupoverly vaccine Development (Anagas)
EFFORT
BU. JAZZ (1-1)
7/16/12
Spor

OTHER SUPPORT: ROTTAZZI, MARIA ELENA

New agent's awarded:

Institute Carlos Simón de Sola 11/15-10/31/18

Private Source: 11/15-10/31/18

NOVA

ACTIVE

EFFORT

Private Source

\$229,019


EFFORT

NOVA

\$33,000

1/1/15 - 12/31/17

ACTIVE



Pending Support

OVER AP

Change for Dr. Shibo Jiang and Lewis D. ...

SHIBO JIANG

ACTIVE

ED01-1000775-04 - Utah - Public Health (D.O.)

E. IMPACT

E.1 WHAT IS THE IMPACT ON THE DEVELOPMENT OF HUMAN RESOURCES?

F. CHANGES

F.1 CHANGES IN APPROACH AND REASONS FOR CHANGE

None

None

Actual grant title: Dr. Huijie Chen and Dr. J. Tony Dong, PI

Subjects

3.a. Human Subjects



1.1



Environmental Health & Safety
Biological & Chemical Safety Program
Materials Management Building, 2412
361 University Blvd. 111

March 14, 2018

Galveston, Texas 77559-1111 Galveston TX 77559-1111
O 409.772.1781 F 409.772.8921

Dear Colleague:

[The following text is extremely faint and largely illegible due to heavy noise and artifacts in the scan. It appears to be the beginning of a letter or report.]



...RR TERMS AND CONDITIONS OF SERVICE AND THE FOLLOWING REGULATIONS...

...2-2010W/NOTICE OF UNLAW...

File Uploaded:
utmb select agent.pdf

5.2 RESPONSIBLE CONDUCT OF RESEARCH

Not Applicable



6. CONFIDENTIALITY OF DATA AND COMMENTS


Not Applicable

14. HUMAN SUBJECTS

6.4.a Does the project involve human subjects?

Yes





National Institutes of Health

Grant Number: CA140007-02

Principal Investigator(s):

Marta Elena Botazzi

SHIBO JIANG MD

Leanne Brooks Scott

Business Official

Business Official

Award e-mailed to: bcmaward@bcm.edu

Budget Period: 05/01/2013 - 04/30/2014

05/01/2013 - 04/30/2017

Project Period: 05/01/2013 - 04/30/2017

U.S. Dollars)

Award Calculation (U.S.

\$955,528

Federal Direct Costs

\$120,702

Federal E&A Costs

\$1,085,321


Federal Share

\$1,085,321

Federal Share

TOTAL FEDERAL AWARD AMOUNT

\$1,085,321



Select Agents if the final registration certificate is denied. _____

Budget	Year 2	Year 3	Year 4	Year 5
--------	--------	--------	--------	--------

TOTAL FEDERAL	\$65,500	\$600,000	\$700,000	\$700,000
---------------	----------	-----------	-----------	-----------


DC

TOTAL FEDERAL	\$109,793	\$224,473	\$282,031	\$282,031
---------------	-----------	-----------	-----------	-----------

F&A

TOTAL COST	\$1,095,224	\$1,194,360	\$1,194,360	\$1,194,360
------------	-------------	-------------	-------------	-------------

Initiation and	Year 2	Year 3	Year 4	Year 5	Year 6
Administrative					



...yeast expression revealed that at least one of our constructs (rBBD193-N1) shows great promise for

are encouraging. We also observed that the protein levels of the mutant were not affected by the presence of the wild-type protein. These data are encouraging and suggest that the mutant is a viable alternative to the wild-type protein. We are currently testing the mutant in a mouse model and will report our findings in a future publication. Figure 2. Western blot analysis of the mutant protein levels in the presence of the wild-type protein. The blot was probed with a conformational epitope-specific mAb 33G4. These data suggest that the mutant is a viable alternative to the wild-type protein. However, we also observed that the protein levels of the mutant were not affected by the presence of the wild-type protein. Figure 2. Western blot analysis of the mutant protein levels in the presence of the wild-type protein. The blot was probed with a conformational epitope-specific mAb 33G4. These data suggest that the mutant is a viable alternative to the wild-type protein.

PRODUCTS C.1 PUBLICATIONS

publications of the research during the reporting period resulting directly from this award?

Yes No

Public Access Compliance

P.J. Readman to developing a recombinant coronavirus S protein receptor-binding

2020-01-01 to 2020-12-31

D. PARTICIPANTS

NA

Y JIANG.

PHD.MD PD/PI

SHIBO,

ao.

Ph.D

Postdoctora

NA

Xiang

Scor ar

Postdoctora

Y.A. Zhai

MD Zhai

Investigator

Elissam

Seid, Chris.-

Ph.D

Staff
scientist
(Doctors)

NA

ID	Name of Person or Entity	Title	Address	City	State	Zip	Phone	Fax	E-mail	Foreign	Origin	Affiliation	a	b	c	d	e	f	g
----	--------------------------	-------	---------	------	-------	-----	-------	-----	--------	---------	--------	-------------	---	---	---	---	---	---	---

S/K - Senior/Key

SS - Supplement Support

